問卷

TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Infectious Disease

更新時間:2023-09-19

王秉槐
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

43Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2025-06-09 - 2029-11-26

Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation
  • Condition/Disease

    Pulmonary Disease, Chronic Obstructive

  • Test Drug

    Prefilled Injectable

Participate Sites
8Sites

Recruiting8Sites

2021-03-01 - 2026-07-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-05-31 - 2027-05-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-07-01 - 2030-01-22

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2026-01-29 - 2031-11-15

Phase II/III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-06-01 - 2028-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-09-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2022-02-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-10-01 - 2029-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5